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Introduction
Low plasma levels of  high-density lipoprotein cholesterol (HDL-C) are associated with increased risks of  
coronary heart disease (CHD) and diabetes mellitus type 2 (T2DM) (1, 2). HDL particles exert diverse 
potentially antiatherogenic and antidiabetic effects (3, 4). Furthermore, atherosclerosis or hyperglycemia 
could be decreased or even reverted in several animal models by transgenic overexpression or exogenous 
application of  apolipoprotein A-I (apoA-I), the most abundant protein of  HDL (3, 4). However, in humans, 
drugs increasing HDL-C such as fibrates, niacin, and inhibitors of  cholesteryl ester transfer protein (CETP) 
have failed to prevent fatal or nonfatal cardiovascular endpoints (2, 5). Moreover, in several inborn errors 
of  human HDL metabolism and genetic mouse models with altered HDL metabolism, low or high HDL-C 
levels were not associated with any differences in cardiovascular risk and atherosclerotic plaque load, 
respectively (2, 3). Because of  these ambiguous data, the causal role and, hence, suitability as a therapeutic 
target of  HDL-C is questioned (2). However, by contrast to the disease-causing cholesterol in LDL (6), the 
cholesterol in HDL (i.e., HDL-C) neither exerts nor reflects any of  the potentially antiatherogenic activities 
of  HDL (3). HDL-C is only a nonfunctional surrogate marker for estimating the HDL pool size without 
deciphering the heterogeneous composition and, hence, functionality of  HDL (2, 3).
High-density lipoproteins (HDL) contain hundreds of lipid species and proteins and exert many 
potentially vasoprotective and antidiabetogenic activities on cells. To resolve structure-function-
disease relationships of HDL, we characterized HDL of 51 healthy subjects and 98 patients with 
diabetes (T2DM), coronary heart disease (CHD), or both for protein and lipid composition, as well 
as functionality in 5 cell types. The integration of 40 clinical characteristics, 34 nuclear magnetic 
resonance (NMR) features, 182 proteins, 227 lipid species, and 12 functional read-outs by high-
dimensional statistical modeling revealed, first, that CHD and T2DM are associated with different 
changes of HDL in size distribution, protein and lipid composition, and function. Second, different 
cellular functions of HDL are weakly correlated with each other and determined by different 
structural components. Cholesterol efflux capacity (CEC) was no proxy of other functions. Third, 
3 potentially novel determinants of HDL function were identified and validated by the use of 
artificially reconstituted HDL, namely the sphingadienine-based sphingomyelin SM 42:3 and 
glycosylphosphatidylinositol-phospholipase D1 for the ability of HDL to inhibit starvation-induced 
apoptosis of human aortic endothelial cells and apolipoprotein F for the ability of HDL to promote 
maximal respiration of brown adipocytes.
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In a prototypic HDL particle, 2–5 molecules of  apoA-I and approximately 100 phosphatidylcholine 
molecules form an amphipathic shell, in which several molecules of  unesterified cholesterol are embedded 
and which surrounds a core of  water-insoluble cholesteryl esters and triglycerides. Differences in the molar 
content of  apoA-I and of  major lipid constituents cause differences of  HDL subclasses in shape, size, and 
charge (3). HDL particles carry hundreds of  different quantitatively minor proteins and lipid species (3), 
many of  which are not just passive cargo (like cholesterol) but are biologically active. This physiological 
heterogeneity is further increased in HDL of  patients — for example, with T2DM or CHD — by the loss or 
structural modification of  typical HDL constituents or by the acquisition of  atypical constituents (7). This 
structural complexity of  HDL is accompanied by functional diversity. The classical function of  HDL is the 
stimulation of  cholesterol efflux (2, 3, 7, 8). In addition, HDL particles also elicit various cellular signal 
transduction processes through interactions of  specific components with specific receptors — for example, 
apoM bound sphingosine-1-phosphate (S1P) with S1P receptors (3, 7). The resulting changes in cellular 
cholesterol homeostasis and signaling events, respectively, have been associated with survival, proliferation, 
and functionality of  cells, including macrophages, endothelial cells, pancreatic β cells, adipocytes, or myo-
cytes (7). Several of  these functions are disturbed in patients with CHD or T2DM (7, 8).
The relative importance of  the many physiological and pathological activities of  normal and dysfunc-
tional HDL, respectively, for the pathogenesis of  atherosclerosis or T2DM is unknown. In a systems biol-
ogy approach (Figure 1), we characterized the size distribution and the lipid and protein composition of  
HDL by nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), as well as the 
functionality of  HDL in 5 cellular systems. Using high-dimensional statistical modeling, specifically prob-
abilistic graphical models, we unraveled several distinct associations of  HDL components with T2DM or 
CHD, as well as cellular functionality of  HDL. Finally, as proof  of  principle, we validated the predicted 
functional relevance of  2 proteins and 1 lipid species by targeted experiments using reconstituted HDL 
(rHDL), which were reconstituted with or without the component of  interest (Figure 1).
Results
Associations of  structural and functional HDL features with disease status. We characterized the structural com-
position and functionality of  HDL in 51 healthy volunteers, 46 patients with T2DM only, 25 patients 
with CHD only, and 27 patients with both T2DM and CHD. As expected, patients and healthy volun-
teers differ significantly by many anthropometric and clinical measures, as well as drug treatment (Sup-
plemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.131491DS1). Supplemental Figures 1–3 show volcano plots of  the disease associations of  34 HDL 
features measured by NMR spectroscopy of  plasma, as well as 182 proteins and 227 lipids measured by 
MS of  isolated HDL. Data are adjusted for sex and sampling site, as well as by date and centrifuge used for 
HDL isolation. All P values are adjusted for multiple testing.
For T2DM, NMR spectroscopy reveals a shift of  HDL particle composition with a loss of  large and 
very large particles and the gain of  small triglyceride-rich particles. The comparison of  CHD patients with 
healthy control subjects does not reveal any significant difference in HDL particle size or composition 
(Supplemental Figure 1).
HDLs of patients with CHD or T2DM (HDLCHD and HDLT2DM, respectively) differ from HDLs of healthy 
controls (HDLhealthy) by the loss of lipid species: In HDLCHD and HDLT2DM, concentrations of 5 and 71 lipid spe-
cies, respectively, are present at significantly lower concentrations. Conversely, only 4 and 14 lipid species occur 
at significantly higher concentrations in HDLCHD and HDLT2DM, respectively, than in HDLhealthy (Supplemental 
Figure 2). Both HDLCHD and HDLT2DM are enriched in phosphatidylethanolamines PE 38:5, PE 38:6, and PE 
40:7. Also of note, all 5 lipid species decreased in HDLCHD are also reduced in HDLT2DM, namely the phosphati-
dylinositols PI 36:2 and PI 34:2, the phosphatidylcholines PC 36:2 and PC 34:2, as well as the cholesteryl ester 
CE 18:2. In addition, HDLT2DM is characterized by strong reductions in the content of ether-phosphatidylcho-
lines (PC O-34:2, PC O-34:3, PC O-36:2, PC O-36:3), lysophosphatidylcholines (LPC 18:2, LPC 18:1, LPC 
18:0), and sphingomyelins (most prominently for SM 42:3 and SM 36:3) (Supplemental Figure 2).
HDLCHD is characterized by the relative enrichment of  specific proteins, whereas HDLT2DM is rather 
deprived of  specific proteins. Compared with HDLhealthy, 6 and 4 proteins are present at significantly higher 
and lower concentrations, respectively, in HDLCHD (Supplemental Figure 3). Conversely, in HDLT2DM, 17 
and 44 proteins are present at significantly higher and lower concentrations, respectively (Supplemental 
Figure 3). Both HDLCHD and HDLT2DM are deprived of  apoA-IV but enriched with pulmonary surfactant 
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protein B (PSPB), as well as serum amyloid A proteins, SAA1 and SAA2. In addition, HDLT2DM is charac-
terized by the loss of  clusterin, paraoxonases PON1 and PON3, and apoD, apoE, apoF, and apoM and the 
gain of  fibrinogen and apoC-II and apoC-III.
Supplemental Table 2 provides an overview of  the in vitro cell culture models that we used for the 
functional testing of  HDL. In mixed-effects models adjusting for sex, sampling site, date, and centrifuge 
used for HDL isolation, as well as plate effects, several functions show statistically significant disease asso-
ciations (Supplemental Figure 4). Effect sizes are presented relative to SDs of  the functional read-outs (see 
Supplemental Methods 5). The ability to promote maximal respiration of  brown adipocytes (respirationmax) 
is increased for HDLCHD (0.68 [95% CI, 0.11–1.3]) but decreased for HDLT2DM (–0.4 [95% CI, –0.77 to 
–0.02]). HDLT2DM is also characterized by reduced ability to inhibit starvation-induced apoptosis of  human 
aortic endothelial cells (HAECs) (apoptosisHAEC) (0.5 [95% CI, 0.15–0.85]). Of  note, the CEC of  neither 
isolated HDL nor apoB-free plasma differs significantly between patients and healthy control subjects.
In order to find independent predictors of  disease status, we used multiple logistic regression with 
elastic net regularization, coupled with stability selection. Figure 2 shows associations of  T2DM, CHD, 
or the combination of  both with several variables in terms of  the regression coefficients (orange and 
green for positive and inverse associations, respectively) and stability selection (diamonds). The more 
conservative stability selection reveals expected associations of  T2DM, CHD, or both, with clinical mea-
sures either defining the disease (e.g., glucose and glycated hemoglobin A1c [HbA1c]) or being risk fac-
tors (age, hypertension), or with effects of  very well-established treatment (lower LDL-C). Only T2DM 
or the combination of  T2DM with CHD show stable associations with HDL-related features (indicated 
by diamonds in Figure 2); HDLT2DM have a reduced ability to lower mitochondrial potential of  myotubes 
after 2 hours (2hr–mitochondrial membrane potential [2hr-MMP] C2C12), a reduced lipid content and 
number of  large particles, and a reduced content of  the IgG FCγ fragment binding protein (FCGBP). 
Also, LPC 22:5 is strongly and inversely associated with T2DM. The combination of  T2DM and CHD 
shows stable positive associations with the content of  PSPB, as well as stable negative associations with 
PI 36:2 and podocalyxin (PODXL). Although weaker and less robust, HDLT2DM+CHD is also characterized 
by a decreased content in apoE and PON1. LPC 18:0 is the only HDL component that is independently 
associated with both T2DM and the combination of  T2DM and CHD. CHD shows several associations, 
but no HDL-related feature persists upon stability selection (no diamonds in Figure 2). Among them, 
the inverse associations with apoA-I and lactate dehydrogenase (LDH) are the strongest, followed by 
extracellular matrix protein 1 (ECM1, inverse), apoA-IV (inverse), secretoglobin family 3A member 2 
Figure 1. Scheme summarizing the strategy and workflow toward a probabilistic graphical model integrating disease sta-
tus with structure of HDL and cellular responses to HDL. FIA-MS/MS, flow injection analysis–tandem mass spectrometry. 
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(SG3A2, positive), and Ras-related protein Rab-1A. Also of  note is the reduced ability of  HDLCHD to 
promote respirationmax of  brown adipocytes and to inhibit the apoptosis of  the pancreatic β cell line 
INS1e (Figure 2).
The heterogeneous associations of HDL functions with either T2DM or CHD are also found by multivar-
iate analysis based on sparse partial least squares (PLS) regression. In Figure 3, disease conditions, as well as 
HDL functions, are modeled jointly as a multivariate response vector in a multiple linear regression model whose 
explanatory variables are the clinical covariates and the read-outs from proteomics, lipidomics, and lipoprotein 
profiling through NMR spectroscopy. In the heatmap, rows and columns are clustered based on correlation 
distance between regression coefficient profiles. As expected, this analysis reveals close similarities between dif-
ferent read-outs of the same bioassay, for example 1h-MMPC2C12 with 10min-MMPC2C12, cAMP-stimulated with 
respirationmax of brown adipocytes. Of note, CECHDL and CECapoB-free plasma cluster rather loosely with other HDL 
functions (see also pairwise correlations in Supplemental Figure 5). Interestingly, the presence of T2DM shows 
the strongest similarity with 2hr-MMPC2C12, which in turn is clustered with MMPC2C12 at different time points, 
Figure 2. Logistic regressions of disease 
conditions as explained by clinical covari-
ates, as well as functional and structural 
features of HDL. Colors indicate the signs 
of the printed regression coefficients 
estimated using elastic net regularization. 
The color intensity reflects the absolute 
value (magnitude) of a given regression 
coefficient. White cells correspond to 
coefficients estimated as zero due to 
regularization. Diamonds indicate features 
chosen by stability selection, with fewer 
than 2 expected false selections per dis-
ease condition.
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apoptosisHAEC, and CECapoB-free plasma. CHD is most similar to the ability of HDL to promote respiration of brown 
adipocytes and apoptosisINS1e. The complex of T2DM/apoptosisHAEC/MMPC2C12 is associated with 2 clusters of  
structural or clinical features; one positively associated cluster encompasses clinical measures of glycemia and 
body mass, as well as several NMR measures of small or medium-sized HDL. The other inversely associated 
cluster encompasses measures of very large HDL, as well as the atypical sphingomyelin SM 42:3 and the ether 
phospholipid PC O-34:3. The complex of CHD/respiration/apoptosisINS1e is also associated with 2 clusters. 
One is positively associated with CHD and characterized by higher activity of HDL to promote mitochondrial 
respiration. This cluster has virtually no association with T2DM but is associated with age, several NMR mea-
sures of large HDL, polyunsaturated phosphatidylethanolamines PE38:5 and PE40:7, apoD, and IL-1 receptor 
accessory protein IL1AP. The other cluster with inverse CHD association also shows inverse association with 
respiration. It contains clinical measures of HDL, such as apoA-I and HDL-C, as well as NMR-based measures 
of HDL-C and small and medium-sized HDL (Figure 3). A part of this cluster is shared between CHD and 
T2DM, but in opposite directions (Figure 3).
Figure 3. Multivariate analysis of disease status and HDL function regressed on HDL structure and subclasses using sparse partial least squares, 
adjusted for clinical covariates. The heat map shows the regression coefficients for features (rows) with respect to responses (columns), and the color 
gradient indicates the magnitude and sign of each coefficient. All features were standardized to have mean zero and variance 1, and the regression 
coefficients should be interpreted in a relative rather than an absolute sense. White cells correspond to coefficients, which — due to sparsity constraints 
— are estimated as zero. Rows and columns are clustered based on correlation distance, thereby indicating similarity of regression coefficient profiles. 
The color code left of the heatmap indicates the data source of each feature.
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Associations of  proteins and lipids with functions of  HDL. We used a Gaussian graphical model to jointly 
analyze conditional dependencies between HDL function and structure, while adjusting for potentially con-
founding clinical covariates. The main result is presented in Figure 4 as a graph in which nodes are clinical, 
functional, and structural features. Two features are connected by an undirected edge if  they are condition-
ally dependent, given all other features in the model. Most functional read-outs have unique relationships 
with clinical features, as well as NMR measures, proteins, and lipids of  HDL particles. There are only very 
few examples where 1 parameter is associated with more than 1 function. Those functions are very closely 
related. For example, apoC-III and S100 protein S10A9 (both positive), LPC 22:5 (negative), as well as free 
cholesterol (FC) in small HDL (positive) and very large HDL (inverse) connect different time points of  
MMPC2C12 (see also partial correlations depicted in Supplemental Figure 6).
Figure 4. Gaussian graphical model estimating conditional dependencies between HDL function, structure, and subclasses, adjusted for clinical 
covariates. For legibility, we show only the bipartite subgraph connecting HDL functions to other features. Edges (lines) indicate partial correlations 
between HDL functions (blue) and proteins (red), lipid species (orange), and abundance of HDL subclasses (violet). Clinical features (green) are included 
to adjust for potential confounding. The gradient edge color indicates whether the corresponding partial correlation is positive (red) or negative (blue).
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CECHDL and CECapoB-free plasma are both predominantly associated with differences in apoA-I measured 
either by the clinical assay, NMR spectroscopy (CECapoB-free plasma), or proteotype analysis (CECHDL). Of  note, 
CECapoB-free plasma shows the strongest correlation with the concentration of  apoA-I and number of  medi-
um-sized HDL particles. CECHDL has more significant correlations — among which, those with PC 30:0, 
PI 36:2, and CE 18:2 are the strongest (Supplemental Figure 6).
ApoptosisHAEC shows several correlations with specific lipids of  HDL. Among them, the inverse with SM 
42:3 is the strongest. LDH (positive) and glycosylphosphatidyl-inositol specific phospholipase D1 (GPLD1, 
inverse) are the only proteins associated with apoptosisHAEC (Figure 4 and Supplemental Figure 6).
LDH is also associated with apoptosisINS1e but in the opposite direction as apoptosisHAEC (Figure 4 and 
Supplemental Figure 6). Other significant correlations are seen with SM 40:1 (inverse), PI 38:3, PE 34:3, 
LPC 18:1, IL1AP, and apoL1 (all positive).
Several NMR measures of  small HDL, S100A9, and apoC-III evolve as the strongest positive determi-
nants of  MMPC2C12. Several glycerophospholipid species are inversely correlated with MMPC2C12. Among 
them, LPC 22:5 is the only measure that shows significant inverse correlations at every time point. Also of  
note, the phospholipid content of  very large and small particles show opposite correlations with MMPC2C12 
at different time points.
The activity of  HDL to promote mitochondrial respiration of  brown adipocytes has several determi-
nants, which surprisingly are not shared between the different phases. The strongest determinants include 
Cathelicidin antimicrobial peptide (CAMP) for respirationcAMP and cathepsin D (CATD) for respirationmax. 
ApoF is another positive determinant of  respirationmax. Interestingly, several lipids emerge as negative deter-
minants of  mitochondrial respiration. Among them, the strongest correlations are found between LPC 22:6 
and respirationbasal, as well as between lysosphingomyelin LSM 18:1 or PC36:4 and respirationmax.
Experimental validation of  structure-function relationships of  HDL. Finally, we validated some of  the struc-
ture-function relationships predicted by the graphical model of  Figure 4. To this end, we used the cho-
late dialysis method to generate rHDL consisting of  apoA-I and dioleyl-phosphatidylcholine (DOPC) in 
a molar ratio of  1:100 with or without the protein or lipid of  interest. The respective candidate proteins or 
lipids are included at 3 different amounts, reflecting the mean, lowest, and highest concentration encoun-
tered in the native HDL samples analyzed in the discovery study (Supplemental Table 3).
We presume that SM 42:3 corresponds to SM d18:2/24:1, which differs from typical sphingomye-
lins by the presence of  an additional Δ14 cis–double bond in the sphingoid base backbone (Supplemental 
Figure 7A). We synthesized this atypical sphingadienine-based sphingomyelin (see Methods section), as 
well as the typical sphingosine-based SM d18:1/24:1 (SM 42:2) as the control lipid (Supplemental Figure 
7). The analysis of  the synthetic SM d18:2/24:1 and SM d18:1/24:1 by liquid chromatography–tandem 
MS (LC-MS/MS) reveals identical chromatographic retention times and fragmentation patterns as for the 
HDL-derived SM 42:3 and SM 42:2, respectively, confirming identity (Supplemental Figure 8). The size 
distribution of  rHDL is not altered by the addition of  either SM 42:3 or SM 42:2 (Supplemental Figure 9). 
Both the sphingadienine-based SM 42:3 and the sphingosine-based SM 42:2 increase the ability of  rHDL 
to inhibit apoptosisHAEC (Figure 5A, P < 0.01 or P < 0.001). A similar, albeit smaller, effect is seen when 
protein-free small unilamellar vesicles (SUVs) consisting of  DOPC are used. In the absence of  sphingomy-
elins, SUVs do not inhibit the apoptosis of  HAECs. However, the incorporation of  either SM 42:2 or SM 
42:3 conveys some antiapoptotic activity to SUVs, which is lower than in rHDL but statistically significant 
(Figure 5B). Neither SM 42:3 nor SM 42:2 alters any other activity of  rHDL (Supplemental Figure 10).
At no concentration did the incorporation of  GPLD1 change the size distribution of  rHDL (Supple-
mental Figure 9). The complementation of  rHDL with GPLD1 improves the ability of  rHDL to inhibit 
apoptosisHAEC (Figure 6A). The antiapoptotic effect of  GPLD1 is encountered at all dosages (Figure 6A, 
P < 0.01). Of  note, GPLD1 inhibits apoptosis of  HAECs only if  associated with rHDL but not as a free 
protein (Figure 6B). The antiapoptotic activity of  rHDL containing GPLD1 is neutralized in the presence 
of  an anti-GPLD1 antibody but not in the presence of  a control IgG (Figure 6C). The addition of  GPLD1 
also increases the ability of  rHDL to inhibit apoptosisINS1e at the medium concentration (Supplemental Fig-
ure 11B, P < 0.01), to reduce MMPC2C12 at medium and high concentrations (Supplemental Figure 11D, P 
< 0.001 and P < 0.05, respectively), and to promote respirationmax and respirationcAMP in brown adipocytes 
at low concentration (Supplemental Figure 11, H and I, both P < 0.05).
The presence of  apoF does not change the size distribution of  rHDL (Supplemental Figure 9). ApoF 
increases the ability of  rHDL to enhance respirationmax at medium concentration (Figure 7, P < 0.05). 
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Interestingly, the addition of  apoF also enhances the ability of  rHDL to inhibit apoptosisINS1e (Supplemen-
tal Figure 12B, P < 0.01 at highest concentration) and to increase MMPC2C12 (Supplemental Figure 12D, 
P < 0.05 at highest concentration).
Discussion
Detailed knowledge of  structure-function-disease relationships of  HDL-associated molecules is a pre-
requisite to test them for their relative physiological and pathogenic importance and to exploit them for 
treatment and diagnostics. We therefore comprehensively and systematically characterized HDL parti-
cles of  51 healthy subjects and 98 patients with either CHD, T2DM, or both. Statistical modeling of  40 
clinical characteristics, 34 NMR features, 182 proteins, 227 lipid species, and 12 functional read-outs 
resulted in the following 3 main findings. First, CHD and T2DM are associated with different changes of  
HDL in protein and lipid composition, as well as functionality. Second, different functions of  HDL show 
rather little correlations with each other and are determined by different structural components. Third, 
we identified and verified 3 potentially novel structural determinants of  HDL functions, namely apoF, 
GPLD1, and the sphingadienine-based sphingomyelin SM 42:3.
Associations of  diseases with distinct structural and functional differences of  HDL. Most previous studies com-
pared HDL of  healthy subjects with HDL of  patients with 1 specific disease for structural differences in 
either size distribution, the proteome, or the lipidome, as well as 1 single function. Therefore, it is unclear 
whether alterations are disease specific and how they interact with each other. By our comprehensive sys-
tems biology approach, we found that, compared with HDLhealthy, HDLCHD and HDLT2DM share some but 
differ by most structural and functional alterations. The few similarities between HDLCHD and HDLT2DM 
observed in the univariate volcano plot analysis (Supplemental Figures 1–3) disappeared upon multiple 
logistic regression with elastic net regularization (Figure 2).
NMR spectroscopy of  plasma revealed the loss of  large and very large HDL particles and the enrich-
ment of  small triglyceride-rich HDL in T2DM (Supplemental Figure 1). Using logistic regression with elas-
tic net regularization, the loss of  very large HDL particles emerged as a stable and independent feature of  
T2DM (Figure 2). Multivariate analysis based on PLS regression also unraveled the association of  T2DM 
with the loss of  very large HDL, but the association with a gain of  small HDL was even stronger (Figure 3). 
These changes are probably caused by increased CETP activity (9–11). Opposite to T2DM, CHD is associ-
ated with the loss of  small and medium-sized HDL and the gain of  large HDL (Figure 3). Previous NMR 
studies also found more consistent and stable associations of  HDL size distribution with T2DM rather than 
Figure 5. Sphingomyelins SM 42:2 and SM 42:3 decrease apoptosis in human aortic endothelial cells (HAECs). (A) Reconstituted HDL (rHDL) contain 
3 different concentrations of SM 42:2 or SM 42:3, which correspond to the lowest, median, and highest concentration relative to phosphatidylcholine in 
native HDL. HAECs were starved in the absence or presence of ± 20 μg/mL rHDL for 16 hours. Apoptosis was recorded by using the free nucleosome assay. 
(B) SM 42:2 and SM 42:3 were reconstituted into unilamellar vesicles with 2 different concentrations. HAECs were starved in absence and presence of uni-
lamellar vesicle ± SM 42:2 or SM 42:3 for 16 hours, and apoptosis was recorded by free nucleosome assay. Data are presented as mean ± SD of 3 indepen-
dent experiments, each with 4 replicates, and were analyzed by 1-way ANOVA coupled with Dunnett’s test for multiple comparisons against rHDL and no 
additives. ***P < 0.001; **P < 0.01; *P < 0.05.
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with CHD (12–17). Like in our study, both present and incident T2DM were previously associated positive-
ly with small HDL and inversely with larger HDL (14, 15), whereas CHD was rather inversely associated 
with small and medium-sized HDL (12).
The lipidomic analysis of  isolated HDL revealed many lipid species at reduced amounts in both HDLCHD 
and HDLT2DM, as compared with HDLhealthy. Compared with HDLCHD, a higher number of  lipid species is 
altered in HDLT2DM upon volcano plot analysis (Supplemental Figure 2), as well as upon the logistic regression 
and multivariate analyses (Figures 2 and 3). Relative to HDLhealthy, both HDLT2DM and HDLCHD are character-
ized by the enrichment of  polyunsaturated PEs and the loss of  PC and PI species that likely contain monoun-
saturated fatty acids (PC 36:2, PC 34:2, PI 36:2, and PI 34:2) (Supplemental Figure 2). However, upon logistic 
regression analysis, none of  these associations remained statistically significant, except the association of  PI 
36:2 with HDLCHD+T2DM (Figure 2). This analysis, however, revealed significant inverse associations of  T2DM 
with lysophosphatidylcholines LPC 22:5 and, less strongly, LPC18:0. LPC18:0, LPC18:2, and LPC22:5 are 
also part of  a cluster encompassing very large HDL, ether phosphatidylcholines, and sphingomyelins; the 
cluster is inversely associated with T2DM (Figure 3). Also of  note are the strong positive associations of  PE 
38:5 and PE 40:7 with CHD upon multivariate analysis based on PLS regression (Figure 3). Ståhlman et al. 
also found LPC 18:1 and LPC 18:2 decreased in HDLT2DM (18). The most prominent and independent inverse 
association of  LPC 22:5 with T2DM (Figure 2) is of  special note in view of  the antiinflammatory effects of  
LPCs containing polyunsaturated fatty acids (19). Ether-PCs were previously reported to be decreased in 
HDLCHD (20) and in HDL of patients with metabolic syndrome (21), whereas others found them increased in 
HDLT2DM (18). Sphingomyelins were reported to be decreased in HDL of patients with metabolic syndrome 
in 1 study but not in another (18, 22). An increased content of  HDL in (polyunsaturated) PEs was previously 
reported for acute coronary syndrome patients and associated with increased thrombogenicity (23–25).
Compared with HDLhealthy, HDLCHD was characterized by the gain of  proteins, whereas HDLT2DM rather 
showed a loss of  proteins in the volcano-plot analysis (Supplemental Figure 3). Both HDLCHD and HDLT2DM 
Figure 6. HDL-associated glycosylphosphatidyl-inositol specific phos-
pholipase D1 (GPLD1) decreases apoptosis in human aortic endothelial 
cells (HAECs). (A) Reconstituted HDL (rHDL) were made with 3 different 
concentrations of GPLD1, reflecting the lowest, median, and highest 
concentration relative to apolipoprotein A-I (apoA-I) encountered in 
native HDL. HAECs were starved in the absence or presence of 20 μg/
mL rHDL. Data represent mean ± SD of 3 independent experiments, 
each with 4 replicates, and were analyzed by 1-way ANOVA coupled with 
Dunnett’s test for multiple comparisons against rHDL. (B) HAECs were 
starved in the absence or presence of 20 μg/mL rHDL ± GPLD1 or 200 ng/
mL free GPLD1 for 16 hours. (C) A total of 25 μg/mL native HDL or rHDL ± 
GPLD1 were preincubated with 1 μg/mL IgG or anti-GPLD1 antibody. Cells 
were starved with HDL or rHDL ± antibodies for 16 hours. Apoptosis was 
recorded by free nucleosome assay. (B and C) Data represent mean ± SD 
of 3 independent experiments, each with 4 replicates, and were analyzed 
by 1-way ANOVA coupled with Tukey’s test for multiple comparisons. 
***P < 0.001; **P < 0.01; *P < 0.05.
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are deprived of  apoA-IV but enriched with PSPB and SAAs (Supplemental Figure 3). The enrichment of  
HDLCHD with SAAs is known to interfere with HDL functions such as CEC and to be an adverse prognostic 
factor (11, 26, 27). However, in our multiple regression analysis, no SAA protein showed any independent 
disease association. By contrast, the inverse association of  apoA-IV with CHD, as well as the positive associ-
ation of  PSPB with the combination of  CHD and T2DM, is stably selected upon logistic regression analysis 
(Figure 2). Previous studies also reported an inverse association of  apoA-IV with the presence and incidence 
of  CHD (28–30). Interestingly, in a previous smaller study, we also found PSPB as the most significantly 
enriched protein of  HDLCHD (31). Longitudinal studies found PSPB-enriched HDL as a significant predictor 
of  mortality in T2DM patients undergoing hemodialysis, as well as in patients with heart failure (32, 33). We 
also found HDLT2DM+CHD and HDLT2DM relatively deprived of  apoE and apoD, respectively (Figure 2), which 
were also inversely associated with prevalent or incident diabetes by others (34). Interestingly, however, the 
PLS regression analysis unraveled the opposite association of  apoD with the CHD cluster (Figure 3).
In agreement with the different structural changes, HDLCHD and HDLT2DM are characterized by distinct 
dysfunctions (Supplemental Figure 4). Of  note, CEC was not associated with any disease state, neither 
upon assessment with the most widely used bioassay of  HDL function (CECapoB-free plasma) (8, 35) nor upon 
recording of  CECHDL with isolated HDL. Several less-frequently investigated functions are specifically 
altered in either HDLCHD or HDLT2DM; HDLT2DM is characterized by reduced anti-apoptotic activity toward 
HAECs and reduced ability to lower the MMP of  C2C12 myotubes. The latter association with T2DM 
remained stable upon logistic regression with elastic net regulation and stability selection (Figure 2), as well 
as upon multivariate analysis based on PLS regression (Figure 3), where T2DM, MMPC2C12, and apopto-
sisHAEC are clustered. Our initial data analyses found the ability of  HDL to promote respirationmax of  brown 
adipocytes associated positively with CHD but inversely with T2DM (Supplemental Figure 4). Upon 
advanced statistical modeling, only the positive association of  respirationmax with CHD persisted (Figures 2 
and 3). In 2 previous studies, we found reduced antiapoptotic activity of  HDLCHD toward HAECs (20, 31), 
which we do not replicate in the present study. In those 2 previous studies, CHD encompassed both diabetic 
and nondiabetic subjects so that we cannot exclude confounding of  CHD with T2DM as the reason for our 
previous finding of  reduced antiapoptotic activity of  HDLCHD.
Structure-function relationships of  HDL. In general, only related functions in the same cell systems, such as 
CECHDL and CECapoB-free plasma, or MMPC2C12 at different time points showed significant correlations (Supplemen-
tal Figure 5) and share the same or similar structural determinants (Figure 4). Distinct functions of HDL in 
different cell models are weakly correlated with one another, if  at all (Supplemental Figure 5). In line with this, 
they share almost no common structural determinant (Figure 4 and Supplemental Figure 6). This divergence is 
of special note for CEC from both a biological and a clinical perspective. HDLs elicit many cellular responses, 
which have been explained by 2 principal paradigms. One paradigm interprets HDL-induced cellular functions 
Figure 7. Apolipoprotein F (apoF) increases maximal respiration of human multipotent adipose–derived stem (hMADS) cells. Reconstituted HDL (rHDL) 
were prepared with 3 different concentrations of apoF, reflecting the lowest, medium, and highest concentration relative to apoA-I encountered in native HDL. 
(A and B) Oxygen consumption rate curves (A) and maximal mitochondrial respiration (B) in brown hMADS cells. Data represent mean ± SD of 3 independent 
experiments, each with 4 replicates, and were analyzed by 1-way ANOVA coupled with Dunnett’s test for multiple comparisons against rHDL. *P < 0.05. 
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as the secondary result of cholesterol efflux and, hence, altered cellular cholesterol homeostasis, which in turn 
results in transcriptional responses of sterol sensitive genes or alters the localization and activity of signaling 
receptors in raft domains of the plasma membrane (3, 7, 36). The other paradigm assumes direct and specific 
interactions between HDL-bound agonists and cellular receptors (3, 7, 37). The weakness of the correlations 
(Figure 2 and Supplemental Figure 5) and the differences in structural determinants (Figure 4 and Supplemental 
Figure 6) observed by us suggest that HDL elicits many actions independently of or in addition to its cholesterol 
efflux–stimulating activities. In this regard, it is noteworthy that we found CEC to be mainly determined by rath-
er unspecific measures, such as HDL-C, apoA-I, small and medium-sized HDL, and different phosphatidylcho-
line species (Figure 4). Previous studies also found apoA-I and phosphatidylcholines, as well as medium-sized 
HDL, as the major determinants of CEC (8, 21, 35, 38). Likewise, Lusis and colleagues found apoA-I and 
medium-sized HDL, rather than any minor HDL proteins, to be the most important explanatory factors of dif-
ferences in CECHDL from different mouse strains (39). Also in line with these and our findings, a recent genome-
wide association study found CECapoB-free plasma associated with variants in genes encoding proteins involved in the 
formation and metabolism of HDL rather than for minor and nonclassical protein components of HDL (40). 
Beyond classical genes of HDL metabolism such as the APOLP1 and APOLP2 loci, CETP, LIPC, or LPL, 
2 loci including the PLB1 and ENPP7 genes — which encode for enzymes degrading phosphatidylcholines 
and sphingomyelins — were the only ones associated with CECapoB-free plasma (40). Thus, general physicochemical 
properties such as number, size, and fluidity of particles rather than specific components appear to determine 
CECHDL. By contrast, we found other functions determined by specific quantitatively minor HDL components 
such as apoC-III and S100A9 (mitochondrial potential of myotubes), apoF and CATD (respiration of brown 
adipocytes), apoL1 (ER stress–induced apoptosis of INS1e cells), or GPLD1 (starvation-induced apoptosis of  
HAECs), which had no impact on CECHDL, neither in the bioinformatics approach (Figure 4) nor in the valida-
tion experiments (Supplemental Figures 11 and 12).
From a clinical point of  view, the weak correlations of  CECHDL or CECapoB-free serum with other functions 
as well as their different structural determinants question the postulated potential of  CEC as an integrative 
proxy of  HDL functionality (35, 41). In several but not all studies, CECapoB-free plasma was found associated 
with the presence and incidence of  CHD, independently of  and more strongly than HDL cholesterol (35, 
41). Moreover, although CETP inhibitor treatment was found to increase CEC (42), this intervention failed 
to prevent CHD events (5). Of  note and in accordance with their clinical futility, treatment with CETP 
inhibitors failed to improve endothelial functionalities of  HDL (43).
Determinants of  HDL functions. The combination of statistical modeling and experimental validation led to 
the identification of 3 determinants of HDL function, namely the sphingadienine-based sphingomyelin SM 42:3 
and GPLD1 for the ability of HDL to inhibit starvation-induced apoptosis of endothelial cells, as well as apoF 
for the ability of HDL to promote respirationmax of brown adipocytes. These 3 molecules are poorly investigated.
Polyunsaturated sphingomyelins SM 36:3, SM 38:3, SM 42:3, and SM 42:4 emerged as determinants of  
HDL’s activities to inhibit starvation-induced apoptosis of  HAECs and lower the mitochondrial potential of  
C2C12 myotubes (Figure 4 and Supplemental Figure 6). Supplementation with SM 42:3 improved the antia-
poptotic activity of  both rHDL and SUVs (Figure 5). The backbone of  SM 42:3 (and probably also the other 
polyunsaturated SMs) differs from that of  typical sphingomyelins by the presence of  sphingadienine, which 
contains 2 double bonds instead of  sphingosine, which has only 1 double bond. The Δ14 cis–double bond gen-
erates an atypical nicked rather than the typical straight backbone of  sphingoid bases (Supplemental Figures 
7 and 8). The sphingadienine-based sphingolipids have been little investigated, although they have been iden-
tified already in the 1960s and constitute 15%–20% of all plasma sphingolipids (44–46). We previously found 
plasma levels of  sphingadienine inversely associated with the risk of  major cardiovascular events during a 
follow-up of  8 years in patients who underwent coronary angiography (44). Most recently, plasma levels of  
sphingadienine-based lipids were found inversely associated with BMI and the HOMA insulin resistance 
index (47). Sphingadienine is likely generated by the desaturation of  sphingosine through an as yet unknown 
enzyme. It is probably metabolized by phosphorylation-like sphinganines and sphingosines, since cells and 
plasma contain sphingadienine-phosphate (S1P d18:2) (20). S1P d18:2 probably acts like sphingosine-1-phos-
phate (S1P d18:1) as an agonist of  sphingosine-1-phosphate receptors (48). In support of  this, the contents of  
HDL in S1P d18:1 and S1P d18:2 show similar correlations with the antiapoptotic activity of  HDL (20). In 
this regard, it is noteworthy that the sphingosine-based SM 42:2 also improved the ability of  both rHDL and 
SUVs to inhibit the apoptosis of  HAECs (Figure 5), as well as the ability of  rHDL to lower MMP of myo-
tubes (Supplemental Figure 10D). SM 42:3, but also other sphingomyelins, transported by HDL may serve as 
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substrates for plasma membrane–located sphingomyelinase, ceramidase, and sphingosine-kinase, which — in 
serial reactions — generate S1P d18:1and S1P d18:2 (48). As agonists of  S1P receptors, they would interfere 
with apoptosis of  HAECs (49). Unfortunately, our lipidomic method did not record S1Ps.
GPLD1, also called GPI-PLD and encoded by the PHLD gene, is mainly produced by the liver. In plasma, 
about 90% of GPLD1 is recovered with apoA-I– or apoA-II–containing lipoproteinslipoproteins (i.e., HDL) 
(50). GPLD1 specifically hydrolyzes the glycan-phosphatidylinositol linkages of GPI-anchored proteins, which 
include essential membrane proteins such as receptors, protease inhibitors, and transporters. GPLD1 is assumed 
to play an important regulatory role for the activity of these proteins. However, little is known on the specific 
relevance of circulating GPLD1. GPLD1 improves the activity of rHDL to inhibit the apoptosis of HAECs 
(Figure 6A). Conversely, the antiapoptotic activity of both native HDL and GPLD1 containing rHDL was low-
ered by a neutralizing anti-GPLD1 antibody (Figure 6C). Of note, GPLD1 was not able to inhibit apoptosis in 
the absence of HDL (Figure 6B). Although not foreseen by the statistical modeling, rHDL increased MMPC2C12, 
as well as respirationcAMP and respirationmax, in the presence of GPLD1. These effects — as well as the associa-
tions of T2DM with the GPLD1 content of HDL, apoptosisHAEC, MMPC2C12, and respirationmax (Supplemental 
Figures 3 and 4) — point to a role of GPLD1 in diabetes. However, data from studies in genetic mouse models 
and humans are controversial. On the one hand, overexpression of hepatic GPLD1 was found to improve oral 
glucose tolerance and to reduce serum triglyceride catabolism in mice (51, 52). On the other hand, the KO of  
Phld in mice ameliorated glucose intolerance and hepatic steatosis under high-fat and high-sucrose diet (53). 
Cross-sectional studies found increased plasma levels of GPLD1 in subjects with prediabetes compared with 
normoglycemic subjects (54) and in patients with diabetes mellitus type 1 compared with both normoglycemic 
subjects and T2DM patients (55). To solve these controversies, it will be important to unravel the mode of action 
of GPLD1 in HDL, notably to identify the GPI-anchored proteins that are shed by GPLD1 and modulate apop-
tosis, as well as mitochondrial potential and respiration.
Finally, we identified apoF as a determinant of  HDL’s ability to promote respirationmax in brown adi-
pocytes (Figures 4 and 7). Although not foreseen by the statistical modeling, apoF also improved the abil-
ity of  rHDL to inhibit the ER stress–induced apoptosis of  INS1e cells (Supplemental Figure 12B). ApoF 
was previously discovered as an endogenous CETP inhibitor (56). Our findings on specific effects of  apoF 
on mitochondrial respiration of  brown adipocytes and ER stress–induced apoptosis of  INS1e cells point to 
specific activities of  apoF, which are independent of  CETP inhibition. In agreement with this, the overex-
pression of  apoF in mice, which lack CETP, decreased HDL cholesterol (57). The KO of Apof had no effect 
on concentrations and size distribution of  HDL and other plasma lipoproteins (58), which is in agreement 
with the size distribution of  rHDL being unaltered by the addition of  apoF (Supplemental Figure 7). Also in 
agreement with our statistical analysis and in vitro experimental data, CECapoB-free plasma was not altered by the 
addition of  apoF (58). In hamsters, which — in contrast to mice — express CETP, RNA interference with 
apoF had no effect on lipoprotein distribution upon chow diet but increased LDL cholesterol and decreased 
HDL cholesterol upon high-fat feeding (59). Interestingly, the additional KO of Apof decreased atherosclerosis 
in Ldlr-KO mice. This effect, however, could not be causally related to the lack of  apoF because the Apof KO 
was associated with hypomorphic expression of  the closely linked Stat2 gene (60). The previously reported 
inverse correlation between plasma levels of  apoF and triglycerides (61, 62) is in agreement with our finding 
of  low apoF levels in HDLT2DM and HDLT2DM+CHD (Supplemental Figure 3).
Limitations and conclusions. Our study has several limitations. First, although — to our knowledge — our 
study is the largest and most comprehensive systems biology study on HDL, the sample number of  our study 
is rather small. Moreover, due to the high prevalence of  asymptomatic atherosclerosis, we cannot rule out 
that some of  our healthy control subjects had CHD. Thus the associations of  specific lipids and proteins with 
T2DM or CHD and, hence, their utility as prognostic biomarkers needs to be validated in targeted longitudi-
nal clinical or epidemiological studies. Second, our findings on specific disease associations of  HDL compo-
nents do not imply any direct or reverse causal relationships. This caveat is not only generally valid, but also 
specifically relevant for our study of  patients and control subjects who were not matched by potential con-
founders. However, our primary aim was to test the hypothesis that T2DM, CHD, and the combination there-
of  cause general alterations of  HDL structure and function. This hypothesis is falsified by our findings. Any 
causal relationship between the disease status and the alterations in the structural composition, structure, and 
functions of  HDL, as well as their directionality, needs to be investigated in targeted experiments and genetic 
studies. Third, the weakness or lack of  correlation between different functions and the finding of  different 
structural determinants may be biased by the analysis of  different functions in different cell culture systems. 
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Indeed, different agonists may be active in different cell system— for example, depending on the expression 
of  receptors. However, the claim of a uniform structure-function relationship of  HDL is driving the use of  
CEC assays in clinical studies. Our findings clearly rule out that CECapoB-free plasma or CECHDL are proxies for all 
other cellular HDL functions. Forth, for most studies, we used transformed and nonhuman cell lines for the 
identification and verification of  agonists or determinants of  HDL function. Whether or not they are relevant 
for primary cells and even more so in vivo needs to be investigated by follow-up studies. Further work is also 
needed to identify the mode of  action by which GPLD1, apoF, and SM 42:3 exert HDL functions.
Methods
Volunteers and patients. Fifty-one healthy volunteers, 46 patients with T2DM only, and 19 patients with both 
T2DM and coronary heart disease (CHD) were recruited at the University Hospital Zurich. Twenty-five 
patients with CHD only and 8 patients with both CHD and T2DM were recruited at Charité Universitäts-
medizin Berlin. As the exclusion criteria, we defined pregnancy, presence of  any acute disease or decom-
pensation of  chronic disease (except acute coronary syndrome), severe chronic kidney disease (eGFR < 30 
mL/min), and active inflammation (C-reactive protein > 10 mg/L or leukocytes > 10 g/L). Data from 2 
patients were omitted due to lacking lipidomic measurements; hence, we report on 149 probands with no 
missing data for HDL function or structure.
A pool plasma was prepared from 3 blood donors to be used as the precision control.
Clinical chemistry and NMR spectroscopy of  plasma. Activities of  liver enzymes, as well as concentrations 
of  total and HDL cholesterol, triglycerides, glucose, creatinine, and CRP, were measured by the use of  a 
COBAS8000 analyzer and assays from Roche Diagnostics. LDL cholesterol was calculated by the Frie-
dewald formula. Concentrations of  apoA-I and apoB were measured by immunonephelometry using the 
BN Prospec and assay from Siemens Healthcare Diagnostics. Lipoprotein(a) (Lp[a]) was measured by the 
use of  a latex enhanced immunoturbidimetric assay from Randox Laboratories Ltd. Glycated hemoglobin 
(HbA1c) was measured by HPLC (ADAMS A1c, ARKRAY).
NMR spectroscopy of lipoproteins was performed by Nightingale Health (http://nightingalehealth.com).
Isolation of  HDL. HDL were isolated by 14 ultracentrifuge runs, each of  which included 11 experi-
mental samples and 1 pool plasma for internal quality control. Two ultracentrifuges were run in parallel, 
yielding 4 batches of  HDL each from 22 study samples and 2 quality controls. Each batch was composed 
of  5 or 6 samples from each study group. Each HDL isolate was diluted to yield the same concentration 
(2 mg/mL) and then divided into appropriate aliquots for each lab. The aliquots were encoded so that the 
analyzing personnel was blind for their patient group assignment. Batches of  22 samples plus controls were 
maintained at 4°C for maximally 3 days until the bioassays were performed. Aliquots for proteomics and 
lipidomics were frozen immediately at –80°C until the analyses were performed in 2 batches of  88 samples 
plus 8 quality control pools and 63 samples plus 6 quality controls.
For the calibration of  the bioassays, we used rHDL (CSL111) provided by CSL Behring.
Preparation of  reconstituted rHDL and SUVs. For functional validation of our candidate lipids and proteins, 
we reconstituted rHDL by the use of the cholate dialysis method (20, 31). rHDL consisted of apoA-I and 
DOPC with or without the protein or lipid of interest. The respective candidate proteins or lipids were included 
at 3 different amounts, reflecting the lowest, median, and highest concentration measured in the native HDL 
samples (Supplemental Table 3). ApoA-I was purified as reported previously (63). DOPC, ApoF, and GPLD1 
were purchased from Avanti Polar Lipids, Aviva Systems Biology, and OriGene Technologies, respectively. For 
neutralization of GPLD1, 25 μg/mL native HDL or rHDL ± GPLD1 were preincubated with 1 μg/mL anti-
GPLD1 antibody (ab192543, Abcam) or control IgG (ab176094, Abcam) for 1 hour. SM 42:3 and SM 42:2 
were synthesized as described below. The size distribution of the HDL particles was analyzed by nondenatur-
ing polyacrylamide gel electrophoresis. SUVs consisted of DOPC and the respective sphingomyelin in molar 
ratios of 66.6:33.3 (SM 42:2 high or SM 42:3 high), 90:10 (SM 42:2 medium or SM 42:3 medium) or 100:0 
(control). The lipid suspension was passed 30 times through a membrane (pore size 200 nm). Thereafter, resid-
ual large particles were removed by centrifugation at 20,000 g for 15 minutes to yield a clear suspension of SUV.
Synthesis of  sphingomyelins SM42:3 and SM42:2. The synthesis of  SM 42:2 (SM d18:1/24:1) and SM 42:3 
(SM d18:2/24:1) is depicted in Supplemental Figure 7A. Details are described in Supplemental Methods 
1. The identity and purity of  SM 42:3 (SM d18:2/24:1) and SM 42:2 (SM d18:1/24:1) were analyzed by 
NMR spectroscopy (not shown). The identity of  synthetic SM d18:2/24:1 and SM d18:1/24:1 with SM 
42:3 and SM 42:2 in HDL was assessed by LC-MS/MS (Supplemental Figure 8).
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Proteomics. HDL was delipidated using an extraction protocol by Wessel and Flügge (64). To control 
for extraction efficiency and reproducibility, bovine α-1-Acid-Glycoprotein (A1AG) was spiked into each 
sample as protein reference prior to digestion. Proteins isolated from HDL underwent tryptic digestion and 
were subsequently analyzed on a QExactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer (Ther-
mo Fisher Scientific) using data-dependent (and data-independent) acquisition schemes (DDA and DIA, 
respectively). Details are described in Supplemental Methods 2.
Lipidomics. Lipids were quantified by direct flow injection electrospray ionization–tandem MS (ESI-
MS/MS) in positive ion mode using the analytical setup and strategy described previously (65, 66). Details 
are described in Supplemental Methods 3.
Bioassays. The characteristics of  bioassays are summarized in Supplemental Table 2.
CEC of  both isolated HDL (CECHDL) and apoB-free plasma (CECapoB-free plasma) was measured as report-
ed by Ritsch et al. (67). In brief, J774 (ATCC, TIB-67) macrophages were radiolabeled with 2.5 μCi/mL 
3H-cholesterol and stimulated with 0.2 mM cAMP (MilliporeSigma) to upregulate ABCA1. The efflux medi-
um containing the stimuli apoB-depleted plasma or HDL was added to the cells for 4 hours. All steps were 
performed in the presence of  5 μg/mL acyl-coenzyme A/cholesterol acyltransferase inhibitor (Sandoz).
To record the antiapoptotic activity of  HDL toward HAECs (Cell Applications Inc., 304-05a), 6 pas-
sages old, and confluently grown HAECs were starved overnight and then incubated with 25 μg/mL native 
HDL or 10 μg/mL CSL111 or 20 μg/mL rHDL. ApoptosisHAEC was recorded by the use of  an ELISA from 
Roche Diagnostics that monitors the amount of  nucleosomes in the cytoplasmic fraction of  cell lysates, 
which occurs in the later phase of  apoptosis.
To record the ability of  HDL to protect β cells from ER stress–induced apoptosis (ApoptosisINS1e), 
62-passages-old and confluently grown cells of  the rat pancreatic β cell line INS1e (provided by C. Woll-
heim, Geneva; ref. 68) were stimulated with 100 nM Thapsigargin (Sigma Aldrich, catalog T9033) and 
incubated with 75 μg/mL native HDL, 10 μg/mL CSL111, or 10 μg/mL rHDL. ApoptosisINS1e was record-
ed by the use of  the Cell Death ELISA from Roche Diagnostics.
Mitochondrial integrity is of paramount importance to cellular health since cells with reduced mitochon-
drial function initiates cytochrome c–dependent apoptosis. Elevated mitochondrial membrane potential (MMP) 
is associated with increased ROS production and therefore is deleterious. To understand the effect of HDL on 
MMP, C2C12 myotubes (ATCC, CRL-1772) were differentiated in vitro for 4 days and serum fasted overnight; 
they were then subjected to serum starvation for 2 hours the following day and incubated with 100 ng/mL of  
HDL for an additional 2 hours. MMP was monitored using the JC-1 fluorescent dye (Abcam, catalog ab141387) 
that accumulates in mitochondria in a voltage-dependent manner (dye was loaded for 30 minutes prior to serum 
starvation). HDL protects against the increase in MMP associated with serum starvation in a dose-dependent 
manner. The experiment was terminated by the addition of CCCP, a protonophore that dissipates the potential 
across the inner mitochondrial membrane, to ensure the reliability of JC-1 as a read-out of MMP.
To study the effect of  HDL derived from healthy and diseased patients on brown adipocyte activity, we 
employed human multipotent adipose-derived stem cells (hMADS) generated and provided by Ez-Zoubir 
Amri from CNRS (Institute of  Biology Valrose, Nice, France); hMADS constitute a unique human cell 
model that can be differentiated into functional brown adipocytes (69). Cells were grown and differen-
tiated into mature white adipocytes on 96-well collagen–coated Seahorse plates. Brown adipocytes were 
obtained by an additional rosiglitazone (Adipogen, catalog 71740; 100 nM) treatment from day 14–17. 
Mature brown adipocytes were exposed to 100 μg/mL of  HDL, rHDL, CSL111, or PBS as control for 
3 hours before measurement of  mitochondrial respiration using the Seahorse 96XF mito-stress test kit. 
After measurement of  the basal respiration, oligomycin (Adipogen, catalog 11342; 1 μg/mL inhibitor of  
complex V; Adipogen, catalog11342) was injected to block respiration coupled to ATP synthesis. Decrease 
in oxygen consumption rate (OCR) following oligomycin injection reflects contribution of  coupled respira-
tion to the basal mitochondrial OCR. Uncoupled respiration was, in the next step, induced with cAMP (0.5 
mM dibutyryl cAMP; Sigma-Aldrich, catalog D0627) to quantify the capacity of  cells to dissipate energy 
through uncoupled respiration. FCCP (Sigma-Aldrich, catalog C2920; 1 μg/mL), a chemical uncoupler, 
was injected to fully uncouple the mitochondrial membrane and to quantify the maximal respiratory capac-
ity of  brown adipocytes. In the last step, rotenone (Sigma-Aldrich, catalog R8875; 3 μM) and antimycin A 
(Sigma-Aldrich, catalog A8674; 2 μg/mL) were injected to block mitochondrial respiration (complex I and 
III) and estimate contribution of  nonmitochondrial respiration to the measured OCR. Nonmitochondrial 
respiration was subtracted to obtain basal, basal uncoupled, cAMP-stimulated uncoupled, and maximal 
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mitochondrial respiration. Using this protocol, we could reliably quantify the effect of  HDL derived from 
healthy and diseased patients on individual parameters of  mitochondrial respiration.
Statistics. The details of all statistical methods are provided in Supplemental Methods 4. In the clinical data, 
approximately 1% of values were missing and were imputed by their predicted values from linear regression 
models fit on all clinical covariates (70). We logarithmically transformed the MS and NMR spectroscopy data 
after adding an estimate of the lower limit of quantification for each feature (71). In order to adjust for nuisance 
variables, we linearly regressed each protein, lipid, or lipoprotein particle feature on indicator variables of dia-
betes, CHD, hospital, sex, and — when applicable — HDL isolation date and centrifuge. Effects of nuisance 
variables were removed, and disease effects were retained for downstream analysis. We used volcano plots to 
visualize univariate associations between disease conditions and abundance of proteins, lipid species, and sub-
classes of HDL. The resulting P values were adjusted for multiple comparisons using the Benjamini-Hochberg 
procedure (72) for controlling the FDR. For the functional bioassays, we used linear mixed-effects models (73) 
to adjust for nuisance variables and plate effects while accommodating technical replicates of HDL samples.
We used logistic regression models to estimate associations between disease conditions and clinical, func-
tional, and structural data. Since the data contained fewer observations than features, and due to the consider-
able correlation among the predictors, we used elastic net regularization (74) in order to make the regression 
problem identifiable. The elastic net parameters were tuned simultaneously using bivariate cross-validation. In 
addition, we used stability selection (75, 76) in order to bound the expected number of falsely selected variables.
In order to leverage the mutual information between disease conditions and HDL functions, we mod-
eled them as a multivariate response vector using PLS regression (77) in a sparse formulation (78) and 
tuned the model parameters through cross-validation.
With the aim of  finding candidate relationships between HDL function and structure, we used a Gauss-
ian graphical model to infer conditional dependencies between continuous-valued features. This amounted 
to estimating partial correlations, which reflect the dependence between each pair of  variables conditioned 
on all other variables in the model, thereby adjusting for the influence of  observed confounders (79). Due 
to the high dimensionality, we regularized the model using the graphical lasso (80). Since the distributions 
of  our features typically had higher kurtosis (heavier tails) than a normal distribution, we used the nonpara-
normal formulation (81) together with a stability approach to tune regularization (82).
Study approval. Ethics approval was obtained from Kantonale Ethikkommission Zurich (PB-BA-
SEC_2015-00159) and Ethikkommission der Charité at Universitätsmedizin Berlin (EA4/123/16). 
All volunteers and patients participated with informed consent.
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